Typhoid Superbugs Outsmart Antibiotics

Typhoid fever, a long-term human ailment, is re-emerging as a serious threat due to the rapid evolution of drug-resistant bacteria. Research published in 2022 revealed that Salmonella enterica serovar Typhi (S. Typhi) is developing extensive drug resistance, increasingly replacing susceptible strains. These extensively drug-resistant (XDR) Typhi strains are not only impervious to frontline antibiotics but are also showing resistance to newer drugs.

While originating primarily in South Asia, these superbugs have demonstrated a propensity for international spread, with nearly 200 instances identified since 1990. Cases have been detected in Southeast Asia, Africa, and even in countries like the UK, US, and Canada. Scientists express grave concern over the speed of this spread, underscoring the necessity of expanding preventative measures, particularly in high-risk regions.

Historically treated with third-generation antimicrobials, typhoid strains now exhibit resistance to common antibiotics. The remaining effective oral antibiotic, azithromycin, is also facing a growing threat from resistance mutations. This development jeopardizes all oral antimicrobial treatments for typhoid, a disease that can be fatal if untreated. Over 13 million cases were reported in 2024.

To combat this escalating crisis, global access to typhoid conjugate vaccines must be expanded. Pakistan has initiated routine immunization, with other countries considering similar steps. The World Health Organization has prequalified four typhoid conjugate vaccines, which are being integrated into childhood immunization programs in endemic countries. Urgent investment in new antibiotic research and widespread vaccination are deemed essential to prevent a future global health catastrophe.